Abstract
Continuous apomorphine infusion has been an established treatment for advanced Parkinson's disease for over two decades. This article reviews the different methods for starting treatment and propose a consensus methodology for it, as well as for the modification of prior treatment, in order to standardize and reduce the variability of clinical practice.
MeSH terms
-
Aftercare
-
Ambulatory Care
-
Antiparkinson Agents / administration & dosage
-
Antiparkinson Agents / therapeutic use*
-
Apomorphine / administration & dosage
-
Apomorphine / adverse effects
-
Apomorphine / therapeutic use*
-
Benserazide / therapeutic use
-
Carbidopa / therapeutic use
-
Caregivers
-
Dopamine Agonists / administration & dosage
-
Dopamine Agonists / therapeutic use*
-
Dose-Response Relationship, Drug
-
Drug Therapy, Combination
-
Humans
-
Infusions, Subcutaneous / standards
-
Levodopa / therapeutic use
-
Parkinson Disease / drug therapy*
-
Patient Education as Topic
-
Patient Selection
-
Retrospective Studies
Substances
-
Antiparkinson Agents
-
Dopamine Agonists
-
Levodopa
-
Benserazide
-
Carbidopa
-
Apomorphine